



DATE: January 15, 2004 SHEET 1 of 2

## Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
	6958.US.02	10/635,342
	APPLICANT(S)	
	BaMaung, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE	GROUP
	08/06/2003	1614

(Use several sheets if necessary)

(37 CFR 1.98 (b))

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Craig, et al., Chemical Abstract. Database accession no. 135:3311987 CA, XP002262659
C2	Database Crossfire Beilstein. Database accession no. brn 5486092, XP002262661; Tetrahedron Letters 33(39):5737-5740 (1992)
C3	Database Crossfire Beilstein. Database accession no. brn 3650004, XP002262660; Tetrahedron Letters 34(47):7557-7560 (1993)
C4	Database Crossfire Beilstein. Database accession no. brn 4803192, XP002262662; Bull. Chem. Soc. Jpn. 65(2):360-365 (1992)
C5	Database Crossfire Beilstein. Database accession no. brn 1721653, XP002262663; Chem Zentralbl 77(II):765 (1906)
C6	Database Crossfire Beilstein. Database accession no. brn 2430446, XP002262664; Bull. Chem. Soc. Jpn. 49:3181-3184 (1976)
C7	Database Crossfire Beilstein. Database accession no. brn 2968669, XP002262665; J. Med. Chem. 33(12):394-407 (1990)
C8	Database Crossfire Beilstein. Database accession no. brn 2970752, XP002262666; J. Med. Chem. 33(1):694-407 (1990)
C9	Database Crossfire Beilstein. Database accession no. brn 3536828, XP002262667; J. Med. Chem. 33(1):694-407 (1990)
C10	Database Crossfire Beilstein. Database accession no. brn 3609285, XP002262668; Tetrahedron 48(10):1853-1868 (1992)
C11	Database Crossfire Beilstein. Database accession no. brn 4230470, XP002262669; J. Org. Chem. 45(12):2288-2290 (1980)
C12	Database Crossfire Beilstein. Database accession no. brn 4231872, XP002262670; Bioorg. Med. Chem. Lett. 10(20):2305-2310 (2000)
C13	Database Crossfire Beilstein. Database accession no. brn 5486837, XP002262671; Tetrahedron Lett. 33(39):5737-5740 (1992)
C14	Database Crossfire Beilstein. Database accession no. brn 5740104, XP002262672; J. Org. Chem. 50(1):91-97 (1985)
C15	Database Crossfire Beilstein. Database accession no. brn 5862099, XP002262673; Tetrahedron Lett. 34(3):504-504 (1993)
C16	Database Crossfire Beilstein. Database accession no. brn 5906442, XP002262674; Tetrahedron Lett. 34(8):1247-1250 (1993)
C17	Database Crossfire Beilstein. Database accession no. brn 6592217, XP002262675; Tetrahedron Lett. 34(47):7557-7560 (1993)
C18	Database Crossfire Beilstein. Database accession no. brn 6844111, XP002262676; Tetrahedron: Asymmetry 5(2):203-206 (1994)


Database Crossfire Beilstein. Database accession no. brn 7566877, XP002262667; J. Antibiot.  
49(9):890-899 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and  
not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)



DATE: August 6, 2003 1 of 1

## Form PTO - 1449 (Modified)

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)  (37 CFR 1.98 (b))	<b>ATTY. DOCKET NO.</b> 6958.US.02	<b>SERIAL NO.</b> (not yet assigned)
	<b>APPLICANT(S)</b> N. BaMaung, et al.	
	<b>FILING DATE</b> August 6, 2003	<b>GROUP</b> (not yet assigned)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
<i>[Signature]</i>	A1	2002-0002152	01/03/02	Craig et al.			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
<i>[Signature]</i>	B1	99/57098	11.11.99	WO		

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>[Signature]</i>	C1	Griffith et al., "Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin", Chemistry and Biology 4(6):461-471 (1997)
<i>[Signature]</i>	C2	Sin et al., "The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2", Proc. Natl. Acad. Sci. USA 94:6099-6103 (1997)

<b>EXAMINER</b> <i>[Signature]</i>	<b>DATE CONSIDERED</b> <i>Sept 7 2004</i>
---------------------------------------	--

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)